Background-Previous cross-sectional studies suggested a positive association between restless legs syndrome (RLS) and coronary heart disease (CHD). This observation was not confirmed by subsequent prospective studies. However, these prospective studies did not take into account the duration of RLS symptoms. Therefore, we prospectively examined whether RLS was associated with an increased risk of CHD in women who participated in the Nurses' Health Study, taking into account the duration of RLS symptoms. Methods and Results-A total of 70 977 women (mean age, 67 years) who were free of CHD and stroke at baseline (2002) were followed up until 2008. Physician-diagnosed RLS was collected via questionnaire. CHD was defined as nonfatal myocardial infarction or fatal CHD. Women with RLS at baseline had a marginally higher risk of developing CHD (multivariable-adjusted hazard ratio, 1.46; 95% confidence interval, 0.97-2.18) compared with women without RLS. The risk was dependent on duration of symptoms: 0.98 (95% confidence interval, 0.44 -2.19) for women with RLS for Ͻ3 years and 1.72 (95% confidence interval, 1.09 -2.73) for women with RLS for Ն3 years (P trendϭ0.03). The multivariable-adjusted hazard ratios of women with RLS for Ն3 years were 1.80 (95% confidence interval, 1.07-3.01) for nonfatal myocardial infarction and 1.49 (95% confidence interval, 0.55-4.04) for fatal CHD relative to women without RLS. Conclusions-We observed that women with RLS for at least 3 years had an elevated risk of CHD. These results suggest that RLS or RLS-associated conditions may contribute to the origin of cardiovascular disease. (Circulation. 2012;126: 1689-1694.)
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The association between RLS and heart disease was first reported in 4000 Swedish men. In that study, participants with RLS more frequently reported heart problems (odds ratio, 2.5). 13 This study was followed by a large multinational sample of European adults that reported an odds ratio of 1.4 between RLS and self-reported heart disease. 14 In the following 10 years, similar significant associations were observed in other studies. 15, 16 However, the cross-sectional design of those studies precludes conclusions on the direction or causality of the observed associations. Excluding the CHD cases at baseline and prospectively examining the association between RLS and incident CHD cases would provide stronger evidence about the causal relationship between RLS and CHD. To date, only 2 studies have prospectively examined RLS and subsequent risk of CHD and failed to find a significant association. 17, 18 However, these studies did not take into account the duration of RLS symptoms as a potential causal factor for CHD.
The purpose of the present study was to prospectively examine whether women in the Nurses' Health Study (NHS) with physician-diagnosed RLS have an increased risk of CHD, taking into account the duration of RLS symptoms.
Methods

Study Population
The NHS cohort was established in 1976, when 121 700 female registered nurses 30 to 55 years of age residing in 11 states responded to a mailed questionnaire concerning their medical histories and health practices. Exposure information and newly diagnosed medical illnesses have been updated every 2 years via mailed questionnaires. 19 In 2002, we asked 82 160 participants in the NHS who were still alive and actively providing feedback on the long version of the questionnaires whether they had ever been diagnosed with RLS by a physician. Therefore, we used 2002 as the baseline in the present analysis and excluded women who had ever reported physiciandiagnosed myocardial infarction (MI), coronary bypass, coronary angioplasty, angina pectoris, or stroke in or before 2002, leaving 70 977 women for this analysis. The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and the Harvard School of Public Health.
Case Ascertainment
We included nonfatal MI and fatal CHD in our end point of CHD. We requested permission to review medical records when a woman reported a nonfatal CHD event. We also sought medical records for deceased participants, whose deaths were identified by families and postal officials and through the National Death Index. Physicians blinded to the participants' questionnaire reports reviewed all medical records. Nonfatal MI and fatal CHD were identified primarily through review of medical records as previously described. 19, 20 MI was confirmed if the criteria of the World Health Organization were met, specifically, on the basis of symptoms and either ECG changes or elevated cardiac enzyme concentrations. 20
Assessment of Physician-Diagnosed RLS and Covariables
In the 2002 survey, the nurses were asked whether they had physician-diagnosed RLS and the date of the first diagnosis. The possible diagnosis dates were 1996 or before, 1997 to 1999, 2000, 2001, or 2002 . Information on potential confounders, including age; body weight; menopause status and estrogen hormone therapy; smoking status; physical activity; use of aspirin, multiple vitamin supplements, antidepressants, antihypertensives, and antiarrhythmics; and a history of major chronic conditions, including hypertension, elevated cholesterol, diabetes mellitus, arthritis, and cancer, was collected via biennial questionnaires throughout the follow-up. Every other year, we also asked the participants whether they had a physical examination in the past 2 years and, if so, whether it was for screening or for symptoms. Body mass index was calculated as weight in kilograms divided by height in meters squared from self-reported weight and height. Dietary intake was collected from validated food frequency questionnaires 21 every 4 years. In 2002, we also collected information on sleep duration and snoring frequency.
Statistical Methods
We categorized participants into 3 groups: no RLS, RLS duration of Ͻ3 years (the midpoint of the RLS duration), and RLS duration of Ն3 years. Person-years for each participant were calculated from the date the 2002 questionnaire was returned to the diagnosed date of CHD or death; June 1, 2008;  or the date of return of their last questionnaire, whichever came first. Time-dependent Cox proportional hazards models were used to estimate age-and multivariableadjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of CHD for women with different RLS durations relative to women without RLS.
We adjusted for age, ethnicity, smoking status, major chronic disease, alcohol drinking, body mass index, physical activity, diet quality as assessed by the Alterative Healthy Eating Index, 22 meno-pause status, sleep characteristics, medication and hormone use at baseline, which may be associated with both CHD 22 and RLS 23 and thus confound their association. Time-varying covariates were also used in the final model except for ethnicity, sleep duration, and snoring frequency.
We examined potential interactions of the presence of RLS (yes versus no) with age (Ͻ65 or Ն65 years, approximate mean age of the studied population), overweight (yes/no, based on body mass index Ն25 kg/m 2 ), smoking status (never versus ever), and physical activity level (top 2 quintiles versus the other 3 quintiles) by including multiplicative terms in the Cox models with adjustment for other potential confounders.
To test the robustness of our observations, we conducted several sensitivity analyses by excluding the women who had ever been diagnosed with diabetes mellitus or arthritis, which are considered common mimics of RLS 24 ; excluding women who had reported frequent snoring, another common sleep complaint; excluding women who had ever been diagnosed with Parkinson disease, cancer, or renal failure by the end of the follow-up; and excluding the CHD cases diagnosed during the first 2 years of follow-up (ie, 2002-2004) to minimize the possibility that these were subclinical or undiagnosed CHD cases at the baseline. There was a possibility that women who were diagnosed as RLS would visit physicians more frequently and thus would be more likely to be found to have CHD. To tackle this potential bias, we conducted a sensitivity analysis by further adjusting for whether participants underwent physical examination for symptoms. We also examined the association between RLS and CHD after excluding those who had physical examination for symptoms; to reduce the residual confounding from the severity of hypertension and diabetes mellitus, we further adjusted for blood pressure, duration of diabetes mellitus, and use of medications for diabetes mellitus.
We used the SAS statistical package (version 9; SAS Institute, Cary, NC) for the analyses. All P values were 2 tailed (PϽ0.05).
Results
At baseline, 1484 of 70 977 women reported having ever been diagnosed with RLS. Compared with women without RLS, women with RLS were more likely to be older, to be white, to use iron supplements, and to have a higher prevalence of major chronic conditions such as hypertension, arthritis, and diabetes mellitus ( Table 1) .
During a mean of 5.6 years of follow-up, we identified 698 incident cases of CHD. A significant association between RLS and CHD was found only among women with longer RLS duration. The multivariable-adjusted HRs were 1.72 (95% CI, 1.09 -2.73) for women with RLS for Ն3 years compared with women without RLS (P trendϭ0.03; Table 2 ). The results did not materially change when we used the continuous variables for covariates (data not shown). The interactions between RLS and other risk factors (older age, overweight, smoking, and low physical activity) were not significant (P for interaction Ͼ0.1 for all).
We further examined the association between RLS and risk of fatal CHD and nonfatal MI specifically. The multivariableadjusted HRs were 1.80 (95% CI, 1.07-3.01) for nonfatal MI ( Table 2 ) and 1.49 (95% CI, 0.55-4.04) for fatal CHD for women with RLS for Ն3 years compared with those without RLS.
We obtained similar results in the sensitivity analyses. Multivariable-adjusted HRs for women with RLS for Ն3 years versus those without RLS were 1.94 (95% CI, 1.11-3.37) for CHD after the exclusion of participants with a history of diabetes mellitus or arthritis, 1.80 (95% CI, 1.09 -2.97) after the exclusion of participants with snoring frequency of every night or most nights, and 2.06 (95% CI, 1.27-3.35) after the exclusion of participants with Parkinson disease, cancer, or renal failure. When we excluded the incident CHD cases diagnosed during the period of 2002 to 2004, the multivariable-adjusted HR was 1.97 (95% CI, 1.13-3.43) for CHD. Comparing women with RLS for Ն3 years and those without RLS gave multivariable-adjusted HRs for CHD of 1.72 (95% CI, 1.09 -2.73) after further adjustment for the self-report of a recent regular physical examination for unspecified symptoms, 1.78 (95% CI, 1.04 -3.03) after further exclusion of participants who reported a physical examination for unspecified symptoms, and 1.70 (95% CI, 1.07-2.68) after further adjustment for blood pressure, diabetes duration, and use of diabetes medications.
Discussion
In this well-established prospective cohort, we observed that women with physician-diagnosed RLS at baseline had a higher risk of developing CHD during 6 years of follow-up. The observed association between RLS and CHD risk appeared to be independent of major known risk factors for CHD such as age, smoking status, physical activity, dietary pattern, body mass index, use of antidepressant medications, history of hypertension, diabetes mellitus, high total cholesterol, short or long sleep duration, and frequent snoring.
The association between RLS and heart disease has been reported in previous cross-sectional studies 13, 14 but has not been confirmed in prospective studies. 17, 18 The South Wales study found a positive but nonsignificant association (adjusted HR, 1.24; 95% CI, 0.89 -1.74) between baseline RLS and increased risk of ischemic heart disease. 17 The Women's Health Study found that RLS was not associated with increased risk of MI among women with an adjusted relative risk of 1.01 (95% CI, 0.65-1.57). 18 However, neither study provided detailed information on the duration of RLS symptoms, thus preventing a direct comparison with our results.
RLS may lead to heart disease through several potential mechanisms: its negative effect on sleep quality and duration, the coexisting sympathetic activation accompanying periodic limb movements of sleep, or the presence of common risk factors for heart disease. Reduced sleep quality could be an intermediate factor between the observed association of RLS and CHD. Insufficient and disturbed sleep has been noted among 75% of primary RLS sufferers. 1 Both short and long sleep duration has been reported to increase the risk of heart disease in our cohort of nurses. 25 In the present study, when we adjusted for sleep duration and snoring frequency or excluded participants with frequent snoring, the association between RLS of at least 3 years' duration and CHD remained significant, suggesting that RLS was not merely leading to CHD through an effect on reduced sleep duration.
The presence of other common chronic conditions and lifestyles in patients with RLS such as hypertension, 10 depression, 11 and obesity, 12 as well as physical inactivity and an unhealthy lifestyle, may also increase the risk of CHD. Although serious diseases such as Parkinson disease, cancer, and renal failure may also confound the association and controlling for those factors attenuated the association notably, the association remained significant. Furthermore, after we excluded women with Parkinson disease, cancer, or renal failure from the analysis, the association persisted.
Individuals with RLS may be at an increased risk of developing CHD because of the presence of periodic limb movements of sleep, 26 seen in 80% of patients with RLS. Coexisting periodic limb movements of sleep are associated with sympathetically mediated elevations in both heart rate and blood pressure. 4 -9 Arousals from sleep have also been shown to increase daytime pulse rate and blood pressure through elevated peripheral sympathetic tone in individuals without periodic limb movements of sleep. 27, 28 The repeated longstanding increased heart rate and blood pressure may in turn increase the risk of CHD. A recent study suggests that RLS is characterized by autonomic dysregulation. 29 The strength of the present study is that we collected detailed information on lifestyle and chronic conditions using validated questionnaires, which enabled us to control for the potential confounders that may be associated with both RLS and heart disease. Another strength is its prospective design. With this prospective approach, the potential for recall and selection biases is reduced. To reduce the bias of possible reverse causation resulting from preclinical or undiagnosed CHD, we reexamined the association between RLS and CHD after excluding the incident cases occurring between 2002 and 2004 and found similar results.
Our study has important limitations that warrant discussion. First, this cohort included mostly white elderly women 30 ; therefore, these findings might not be generalizable to younger individuals, men, or nonwhite female populations. The rate of incident CHD in this population (1.75 events/1000 person-years) was lower than the age-standardized rate reported in the Atherosclerosis Risk in Communities (ARIC) study (4.4 events/1000 person-years in white women), 31 a representative sample of US adults. 32 The risk of CHD is even greater among men and black women. 31 Compared with the general population, the participants in our cohort were rela-tively healthy, which has been reported in a previous study. 30 For example, the prevalence of obesity was 35% in non-Hispanic white women Ն40 years of age in the 2001 to 2002 National Health and Nutrition Examination Survey 33 compared with 23% in the present cohort in 2002. However, the relative homogeneity of the study population in educational attainment and socioeconomic status enhances the internal validity of this study, which is the basis of generalizability.
Second, we collected information only on physiciandiagnosed RLS cases. However, because RLS is generally underdiagnosed, 34 the prevalence of 2.4% observed in the entire NHS (including those with cardiovascular disease at the baseline) might underestimate the true prevalence. In previous studies, Ϸ6% to 11% of women 1, 12, 35, 36 and 4% to 8% of men 12, 16, 20, 37 were found to have RLS, as assessed by detailed questionnaires or in-person interviews. Thus, misclassification of RLS as non-RLS in the present study is inevitable. If participants with RLS were misclassified as not having RLS, the observed HRs reflect a bias toward a null and an underestimation of the true effect. However, it might also lead to a selective identification of women with more severe RLS; thus, our results may not be applicable to all , menopausal status (premenopausal or postmenopausal), menopausal hormone use (never, past, or current user), alcohol intake (0, 0.1-4.9, 5.0 -9.9, 10.0 -14.9, and Ն15 gram a day), physical activity (quintiles), Alterative Healthy Eating Index (quintile), and use of aspirin (yes or no). ‡Model 2: further adjusted for use of antidepressant, antihypertensive, and antiarrhythmic medication and the presence of diabetes mellitus, arthritis, hypertension, high cholesterol, Parkinson disease, cancer, or renal failure (yes/no for each) at baseline. women with RLS. Further studies using more precise diagnostic strategies for identifying RLS in the community are warranted.
Third, we cannot exclude the possibility that the association of RLS and CHD may be due to RLS treatment, especially among individuals with a long duration of RLS. Several RLS treatments, including low-dose pergolide, have been reported to be associated with a higher risk of valvular heart disease. 38, 39 However, on the basis of the results from the RLS Epidemiology, Symptoms, and Treatment (REST) primary care study, 40 patients with RLS were generally not treated with dopamine agents (like pergolide) during this time period.
Fourth, although we had already adjusted for a wide range of potential confounders, we could not rule out the possibility of residual confounding such as the severity of hypertension and diabetes mellitus. To address this issue, we performed a sensitivity analysis by further adjusting for blood pressure, duration of diabetes mellitus, and use of diabetes medications; the results did not change materially. Finally, we followed up these patients for a mean of only 5.6 years. However, given that, in this short period of time, RLS patients with longer disease duration were more likely to have heart disease, we anticipate that longer periods of follow-up would show an even stronger association between RLS and heart disease. Such longer-term follow-up studies need to be performed.
Despite these limitations and even in the absence of a clear understanding of the mechanism, or if RLS turns out to be a marker for some other as-yet unknown risk factor for CHD, the fact that RLS independently predicted CHD may have practical implications for selecting a high-risk population for future primary prevention.
Conclusions
In this large-scale prospective study, we found that women with physician-diagnosed RLS of at least 3 years' duration had a higher risk of developing CHD during 6 years of follow-up. The fact that the association between RLS and cardiovascular diseases was found only for women with longer duration RLS suggests that the long-term impact of RLS or RLS-associated conditions may contribute to cardiovascular disease. Among other possibilities, this may occur through the well-known increased sympathetic activation seen in RLS. 29 Future study is needed to verify these associations and their respective hypotheses. Investigating the potential effects of RLS on disease progression and mortality in CHD patients is also warranted.
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